Weil E H, Ruiz-Cerdá J L, Eerdmans P H, Janknegt R A, Bemelmans B L, van Kerrebroeck P E
Department of Urology, University Hospital Maastricht, The Netherlands.
Eur Urol. 2000 Feb;37(2):161-71. doi: 10.1159/000020134.
To compare the effectiveness of sacral root neuromodulation with that of conservative management in ameliorating symptoms of refractory urinary urge incontinence and enhancing quality of life, to assess the objective response to neuromodulation as revealed by urodynamic testing, and to delineate the long-term outcomes of neuromodulation.
Forty-four patients with refractory urge incontinence were randomized to undergo neuromodulation with an implantable impulse generator (n = 21) or to continue their prior conservative management (n = 23). At 6 months the control group was eligible for crossover to implant. Patient evaluation included voiding diaries, quality of life questionnaires, urodynamic testing, and documentation of adverse events. Long-term follow-up evaluations were conducted at 6-month intervals up to 36 months.
At 6 months mean leakage episodes, leakage severity and pad usage in the implant group were significantly lower by 88% (p < 0.0005), 24% (p = 0.047) and 90% (p < 0.0005), respectively, than the corresponding control group mean values. Improvements in leakage episodes and pad usage of >/=90% were attained by 75 and 85% of the implant group, respectively, but none of the control group. One third of implant patients, but none of the control patients, achieved >/=50% improvement in leakage severity. Over half of the implant patients (56%) were completely dry compared with 1 control patient (4%). Implant patients, but not control patients, exhibited significant improvement with respect to two quality of life measures. Neuromodulation resulted in increases of 220% (p < 0.0005) and 39% (p = 0.013), respectively, in urodynamically assessed bladder volume at first contraction and maximum fill. At 36 months the actuarial rate of treatment failure was 32.4% (95% CI, 17.0-56.0%). Adverse events most frequently involved pain at the implant site, and the incidence of serious complications was low.
Neuromodulation is markedly more effective than conservative management in alleviating symptoms of refractory urge incontinence. Quality of life and urodynamic function are also improved by neuromodulation. The effects of neuromodulation are long-lasting, and associated morbidity is low.
比较骶神经根神经调节与保守治疗在改善难治性急迫性尿失禁症状及提高生活质量方面的有效性,评估尿动力学检查所显示的神经调节客观反应,并描述神经调节的长期效果。
44例难治性急迫性尿失禁患者被随机分为两组,一组接受植入式脉冲发生器神经调节治疗(n = 21),另一组继续之前的保守治疗(n = 23)。6个月时,对照组有资格交叉接受植入治疗。患者评估包括排尿日记、生活质量问卷、尿动力学检查以及不良事件记录。每6个月进行一次长期随访评估,直至36个月。
6个月时,植入组的平均漏尿次数、漏尿严重程度和护垫使用量分别比相应对照组平均值显著降低88%(p < 0.0005)、24%(p = 0.047)和90%(p < 0.0005)。植入组分别有75%和85%的患者漏尿次数和护垫使用量改善≥90%,而对照组无一例达到。植入组三分之一的患者漏尿严重程度改善≥50%,而对照组无一例。超过一半的植入患者(56%)完全无漏尿,而对照组只有1例患者(4%)。植入患者在两项生活质量指标上有显著改善,而对照组患者则无。神经调节使尿动力学评估的首次收缩膀胱容量和最大充盈膀胱容量分别增加220%(p < 0.0005)和39%(p = 0.013)。36个月时,治疗失败的精算率为32.4%(95%可信区间,17.0 - 56.0%)。不良事件最常见的是植入部位疼痛,严重并发症的发生率较低。
在缓解难治性急迫性尿失禁症状方面,神经调节明显比保守治疗更有效。神经调节还可改善生活质量和尿动力学功能。神经调节的效果持久,且相关发病率较低。